Olon Group Announces Acquisition of GTP Bioways Group

MILAN, July 3, 2024 (GLOBE NEWSWIRE) — GTP Bioways Group is a French company operating as a Biotech CDMO (Contract Developing and Manufacturing Organisation), specializing in R&D services, process development and production of mAbs, enzymes, proteins, nanomedicines, ADCs and F&F. GTP Bioways Group, with multiple locations throughout France, specializes in providing comprehensive services to biopharmaceutical companies. From preclinical development to commercial stages, the group focuses on using cutting-edge technologies to develop innovative therapies.

GTP Bioways Group services are seamlessly integrated with those of Olon Biotech. This integration enables Olon Biotech to expand and diversify its technology offering, supporting every stage of the life cycle, from R&D and preclinical to industrialization, through microbial and mammalian fermentation and biotherapeutics. In addition, Olon Biotech will provide comprehensive services for the development and production of innovative classes of ADCs, offering a complete solution from monoclonal antibodies to linkers, payloads, conjugation and fill and finish processes.

GTP Bioways operates a total of four sites in France (Toulouse, Labege, Veyre-Monton and Saint-Julien-en-Genevois) focused on development, clinical trials and cGMP manufacturing. The headquarters is located in Toulouse.

All four centres operate to the highest quality standards, in accordance with GMP guidelines, and are regularly inspected by the relevant regulatory authorities.

The business areas in which GTP Bioways focuses include the production of biologics and ADC production (using mammalian and microbial fermentation technologies), the production of nanomedicines, filling and finishing, and analytical development – ​​including HCP and immunoanalysis. In particular, the company has consolidated a strong experience in the business areas in which it operates. This is confirmed by a significant number of successfully developed biological processes, the management of a wide and diversified range of expression systems (mammalian cells, bacteria, yeast, insects) and molecules (mAbs, antibody fragments, cytokines, fusion proteins, enzymes, antigens). In addition, the group has significant experience in bioconjugation and filling and finishing. The offered CDMO services create an integrated platform able to support customers from drug discovery through the entire development process, with a special focus on the preclinical phase, Phase I and Phase II.

The story continues

Since its foundation, Olon Group has consistently pursued a strategy of growth, consolidation and expansion in the global market through internal development and strategic acquisitions. Each acquired company has brought valuable experience, enhancing Olon’s technological capabilities. In line with this strategy and with the aim of promoting innovative and technologically advanced offerings for customers, Olon has acquired GTP Bioways Group. The specific capabilities of GTP Bioways Group to fully support CDMO biotechnology projects also in the early stages of development of new molecules (preclinical, Phase I and Phase II) perfectly complement Olon’s current assets to enrich and broaden the offering for customers.

“The acquisition of GTP Bioways Group represents a strong and significant reinforcement of Olon’s service offering, with the aim of creating new business opportunities, acquiring new customers and high-potential market areas, and ultimately continuing the company’s growth.” he stated Paolo Tubertini, CEO, Olon Group.

In Q3 2024, Olon will complete its EUR 25 million investment in an extremely secure facility fully dedicated to the development and production of Ultra High Potent APIs – payloads and payload linkers for antibody-drug conjugates (ADCs). Olon builds on over 40 years of experience in the production of cytotoxic products. With the acquisition of GTP Bioways, Olon Biotech will be able to offer a full-service ADC development and production facility, capable of delivering everything from monoclonal antibodies to payloads, conjugation, and fill and finish.

Contact details – Sabrina Spina, Olon Press Office. [email protected] / +39 338 6674289